Connection
Daniel Matlock to Cost-Benefit Analysis
This is a "connection" page, showing publications Daniel Matlock has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.404 |
|
|
|
-
Venechuk GE, Allen LA, Doermann Byrd K, Dickert N, Matlock DD. Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan. Circ Cardiovasc Qual Outcomes. 2020 09; 13(9):e006255.
Score: 0.153
-
Sandhu A, Levy A, Varosy PD, Matlock D. Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy in Older Adults With Heart Failure. J Am Geriatr Soc. 2019 10; 67(10):2193-2199.
Score: 0.143
-
Matlock DD. Defibrillators in heart failure and quality of life. N Engl J Med. 2009 Jan 08; 360(2):187-8; author reply 189.
Score: 0.069
-
Dickert NW, Mitchell AR, Venechuk GE, Matlock DD, Moore MA, Morris AA, Pierce KJ, Speight CD, Allen LA. Show Me the Money: Patients' Perspectives on a Decision Aid for Sacubitril/Valsartan Addressing Out-of-Pocket Cost. Circ Cardiovasc Qual Outcomes. 2020 12; 13(12):e007070.
Score: 0.039